A study to evaluate an investigational drug designed to inhibit receptors that are believed to contribute to migraine attacks.
This study lasts up to 55 weeks, in which participants will be screened, go through two phases of treatment and have a follow-up visit.
Participants will be randomly assigned to receive the investigational drug or a placebo.
Several treatments are available to help ease Alzheimer’s symptoms; however, none of these existing treatments are capable of slowing the progression of the disease and protecting the brain from further damage. Clinical researches are developing new treatments that may slow the progression of Alzheimer’s.
The SUVN-502 Study is to test whether an investigational medication,
A Randomized, Placebo controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease. (Prodromal AD)
This is an 18 month study in which subjects that screen and qualify will go onto the program taking the investigation medication by mouth once daily.
